Table 1.
Characteristics of respondents
| Respondent | Race/ethnicity | Age (years) | Approximate time since diagnosis (years) | Interview round | S2K RI-50 score (closest visit to interview) | Medication (closest visit to interview) | FM (yes/no) |
|---|---|---|---|---|---|---|---|
| A | African-American | 26 | 2 | 1 | N/A | None | No |
| N/A | N/A | None | |||||
| B | African-American | 46 | 20 | 1 | N/A |
BEL HCQ |
No |
| 2 | N/A |
BEL HCQ |
|||||
| C | White | 40 | 6 | 1 | N/A |
RTX MMF PDN |
Yes |
| N/A | N/A | N/A | |||||
| D | African-American | 31 | 7 | 1 | 0 |
AZA HCQ PDN |
No |
| 2 | 0 |
AZA HCQ PDN |
|||||
| E | White | 42 | 2 | 1 | 6 | HCQ | No |
| 2 | 5 |
HCQ PDN |
|||||
| F | White | 40 | 7 | 1 | 0 |
LEU HCQ PDN |
No |
| 2 | 0 |
HCQ PDN |
BEL: belimumab; PDN: prednisolone; HCQ: hydroxychloroquine; AZA: azathioprine; LEU: leflunomide; MMF: mycophenylate mofetil; RTX: rituximab; S2K RI-50: Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50